{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T09:45:53Z","timestamp":1794649553731,"version":"4.9.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T00:00:00Z","timestamp":1527724800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12913-018-3162-2","type":"journal-article","created":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T12:23:20Z","timestamp":1527769400000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6382-1795","authenticated-orcid":false,"given":"Liz","family":"Morrell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Wordsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Schuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Middleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sian","family":"Rees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W.","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,31]]},"reference":[{"key":"3162_CR1","volume-title":"Value based assessment of drugs","author":"The Parliamentary Office of Science and Technology","year":"2015","unstructured":"The Parliamentary Office of Science and Technology. Value based assessment of drugs. 2015. researchbriefings.files.parliament.uk\/documents\/POST-PN-487\/POST-PN-487.pdf."},{"key":"3162_CR2","unstructured":"National Audit Office. Investigation into the Cancer Drugs Fund. 2015. https:\/\/www.nao.org.uk\/report\/investigation-into-the-cancer-drugs-fund\/ ."},{"key":"3162_CR3","doi-asserted-by":"publisher","first-page":"g7276","DOI":"10.1136\/bmj.g7276","volume":"349","author":"M Buxton","year":"2014","unstructured":"Buxton M, Longworth L, Raftery J, Sculpher M, Towse A. Reforming the Cancer drug fund. BMJ. 2014;349:g7276. https:\/\/doi.org\/10.1136\/bmj.g7276 .","journal-title":"BMJ"},{"issue":"8","key":"3162_CR4","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/hec.2872","volume":"22","author":"WG Linley","year":"2013","unstructured":"Linley WG, Hughes DA. Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in great Britain. Health Econ. 2013;22(8):948\u201364.","journal-title":"Health Econ"},{"issue":"6","key":"3162_CR5","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.jval.2016.04.001","volume":"19","author":"P Dixon","year":"2016","unstructured":"Dixon P, Chamberlain C, Hollingworth W. Did it matter that the Cancer drugs fund was not NICE? A retrospective review. Value Health. 2016;19(6):879\u201384. http:\/\/dx.doi.org\/10.1016\/j.jval.2016.04.001","journal-title":"Value Health"},{"key":"3162_CR6","volume-title":"PMG19 addendum a - final amendments to the NICE technology appraisal processes and methods guides to support the proposed new Cancer drugs fund arrangements","author":"NICE","year":"2016","unstructured":"NICE. PMG19 addendum a - final amendments to the NICE technology appraisal processes and methods guides to support the proposed new Cancer drugs fund arrangements. 2016 https:\/\/www.nice.org.uk\/Media\/Default\/About\/what-we-do\/NICE-guidance\/NICE-technology-appraisals\/process-and-methods-guide-addendum.pdf ."},{"key":"3162_CR7","doi-asserted-by":"publisher","unstructured":"McCabe C, Chilcott J, Claxton K, Tappenden P, Cooper C, Roberts J, et al. Continuing the multiple sclerosis risk sharing scheme is unjustified. BMJ. 2010;340 https:\/\/doi.org\/10.1136\/bmj.c1786 .","DOI":"10.1136\/bmj.c1786"},{"key":"3162_CR8","volume-title":"Final evaluation determination: Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene","author":"NICE","year":"2016","unstructured":"NICE. Final evaluation determination: Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene. 2016 https:\/\/www.nice.org.uk\/guidance\/GID-DUCHENNEMUSCULARDYSTROPHY\/documents\/final-evaluation-determination-document ."},{"issue":"2","key":"3162_CR9","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.healthpol.2014.10.013","volume":"119","author":"W Boon","year":"2015","unstructured":"Boon W, Martins L, Koopmanschap M. Governance of conditional reimbursement practices in the Netherlands. Health Policy. 2015;119(2):180\u20135. http:\/\/dx.doi.org\/10.1016\/j.healthpol.2014.10.013","journal-title":"Health Policy"},{"issue":"4","key":"3162_CR10","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1017\/S0266462315000446","volume":"31","author":"S Montilla","year":"2015","unstructured":"Montilla S, Xoxi E, Russo P, Cicchetti A, Pani L. Monitoring registries at Italian Medicines Agency : fostering access, guaranteeing sustainability. Int J Technol Assess Health Care. 2015;31(4):210\u20133. https:\/\/doi.org\/10.1017\/S0266462315000446 .","journal-title":"Int J Technol Assess Health Care"},{"issue":"6","key":"3162_CR11","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/cpt.508","volume":"100","author":"SD Faulkner","year":"2016","unstructured":"Faulkner SD, Lee M, Qin D, Morrell L, Xoxi E, Sammarco A, et al. Pricing and reimbursement experiences and insights in the European Union and the United States: lessons learned to approach adaptive payer pathways. Clinical Pharmacology & Therapeutics. 2016;100(6):730\u201342. https:\/\/doi.org\/10.1002\/cpt.508 .","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"1","key":"3162_CR12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/1056492610375988","volume":"20","author":"D Hannah","year":"2011","unstructured":"Hannah D, Lautsch B. Counting in qualitative research: why to conduct it, when to avoid it, and when to closet it. Journal of Management Enquiry. 2011;20(1):14\u201322. https:\/\/doi.org\/10.1177\/1056492610375988 .","journal-title":"Journal of Management Enquiry"},{"key":"3162_CR13","volume-title":"Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen (TA316)","author":"NICE","year":"2014","unstructured":"NICE. Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen (TA316) 2014. https:\/\/www.nice.org.uk\/guidance\/ta316 ."},{"key":"3162_CR14","volume-title":"Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib (TA338)","author":"NICE","year":"2015","unstructured":"NICE. Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib (TA338). 2015. https:\/\/www.nice.org.uk\/guidance\/ta338 ."},{"key":"3162_CR15","volume-title":"Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)","author":"NICE","year":"2016","unstructured":"NICE. Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412) 2016. https:\/\/www.nice.org.uk\/guidance\/ta412 ."},{"key":"3162_CR16","volume-title":"Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer (TA310)","author":"NICE","year":"2014","unstructured":"NICE. Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer (TA310) 2014. https:\/\/www.nice.org.uk\/guidance\/ta310 ."},{"key":"3162_CR17","volume-title":"Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane (TA371)","author":"NICE","year":"2015","unstructured":"NICE. Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane (TA371) 2015. https:\/\/www.nice.org.uk\/guidance\/ta371 ."},{"key":"3162_CR18","volume-title":"Ramucirumab for treating advanced gastric cancer or gastro\u2013oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378)","author":"NICE","year":"2016","unstructured":"NICE. Ramucirumab for treating advanced gastric cancer or gastro\u2013oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378) 2016. https:\/\/www.nice.org.uk\/guidance\/ta378 ."},{"key":"3162_CR19","volume-title":"Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer (TA309)","author":"NICE","year":"2014","unstructured":"NICE. Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer (TA309) 2014. https:\/\/www.nice.org.uk\/guidance\/ta309 ."},{"key":"3162_CR20","unstructured":"NICE. Guide to the methods of technology appraisal 2013. https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/foreword ."},{"key":"3162_CR21","volume-title":"Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307)","author":"NICE","year":"2014","unstructured":"NICE. Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307) 2014. https:\/\/www.nice.org.uk\/guidance\/ta307 ."},{"key":"3162_CR22","volume-title":"Bortezomib for previously untreated mantle cell lymphoma (TA370)","author":"NICE","year":"2015","unstructured":"NICE. Bortezomib for previously untreated mantle cell lymphoma (TA370). 2015 https:\/\/www.nice.org.uk\/guidance\/ta370 ."},{"key":"3162_CR23","volume-title":"Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)","author":"NICE","year":"2016","unstructured":"NICE. Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384) 2016. https:\/\/www.nice.org.uk\/guidance\/ta384 ."},{"key":"3162_CR24","unstructured":"NICE. Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation (TA311) 2014. https:\/\/www.nice.org.uk\/guidance\/ta311 ."},{"key":"3162_CR25","volume-title":"Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (TA323)","author":"NICE","year":"2014","unstructured":"NICE. Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (TA323) 2014. https:\/\/www.nice.org.uk\/guidance\/ta323 ."},{"key":"3162_CR26","volume-title":"Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA321)","author":"NICE","year":"2014","unstructured":"NICE. Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA321) 2014. https:\/\/www.nice.org.uk\/guidance\/ta321 ."},{"key":"3162_CR27","volume-title":"Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)","author":"NICE","year":"2015","unstructured":"NICE. Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366) 2015. https:\/\/www.nice.org.uk\/guidance\/ta366 ."},{"key":"3162_CR28","volume-title":"Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non-small-cell lung cancer (TA347)","author":"NICE","year":"2015","unstructured":"NICE. Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non-small-cell lung cancer (TA347) 2015. https:\/\/www.nice.org.uk\/guidance\/ta347 ."},{"key":"3162_CR29","volume-title":"Idelalisib for treating chronic lymphocytic leukaemia (TA359)","author":"NICE","year":"2015","unstructured":"NICE. Idelalisib for treating chronic lymphocytic leukaemia (TA359)2015. https:\/\/www.nice.org.uk\/guidance\/ta359 ."},{"key":"3162_CR30","volume-title":"Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy (TA381)","author":"NICE","year":"2016","unstructured":"NICE. Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy (TA381)2016. https:\/\/www.nice.org.uk\/guidance\/ta381 ."},{"key":"3162_CR31","volume-title":"Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)","author":"NICE","year":"2015","unstructured":"NICE. Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)2015. https:\/\/www.nice.org.uk\/guidance\/ta357 ."},{"key":"3162_CR32","volume-title":"Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (TA374)","author":"NICE","year":"2015","unstructured":"NICE. Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (TA374)2015. https:\/\/www.nice.org.uk\/guidance\/ta374 ."},{"key":"3162_CR33","volume-title":"Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)","author":"NICE","year":"2014","unstructured":"NICE. Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319) 2014. https:\/\/www.nice.org.uk\/guidance\/ta319 ."},{"key":"3162_CR34","volume-title":"Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)","author":"NICE","year":"2015","unstructured":"NICE. Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343) 2015. https:\/\/www.nice.org.uk\/guidance\/ta343 ."},{"key":"3162_CR35","volume-title":"Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer (TA360)","author":"NICE","year":"2015","unstructured":"NICE. Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer (TA360) 2015. https:\/\/www.nice.org.uk\/guidance\/ta360 ."},{"key":"3162_CR36","unstructured":"NICE. Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (TA322) 2014. https:\/\/www.nice.org.uk\/guidance\/ta322 ."},{"key":"3162_CR37","doi-asserted-by":"publisher","first-page":"i5090","DOI":"10.1136\/bmj.i5090","volume":"354","author":"R Grieve","year":"2016","unstructured":"Grieve R, Abrams K, Claxton K, Goldacre B, James N, Nicholl J, et al. Cancer drugs fund requires further reform. BMJ. 2016;354:i5090.","journal-title":"BMJ"},{"key":"3162_CR38","volume-title":"Avelumab for merkel cell carcinoma (ID1102)","author":"NICE","year":"2018","unstructured":"NICE. Avelumab for merkel cell carcinoma (ID1102) 2018. https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-ta10136\/documents ."},{"key":"3162_CR39","volume-title":"Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer: managed access agreement","author":"NICE","year":"2016","unstructured":"NICE. Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer: managed access agreement. 2016. https:\/\/www.nice.org.uk\/guidance\/ta416\/resources ."},{"key":"3162_CR40","volume-title":"Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA492)","author":"NICE","year":"2017","unstructured":"NICE. Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA492) 2017. https:\/\/www.nice.org.uk\/guidance\/ta492\/resources .."},{"key":"3162_CR41","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/oso\/9780192631770.003.0008","volume-title":"Economic evaluation in health care: merging theory and practice","author":"A Briggs","year":"2001","unstructured":"Briggs A. Handling uncertainty in economic evaluation and presenting the results. In: Drummond MF, McGuire A, editors. Economic evaluation in health care: merging theory and practice. Oxford: Oxford University Press; 2001. p. 172\u2013214."},{"key":"3162_CR42","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation. Handbooks in health economic evaluation","author":"A Briggs","year":"2006","unstructured":"Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Handbooks in health economic evaluation. Oxford: Oxford University Press; 2006."},{"key":"3162_CR43","volume-title":"Applied methods of cost-effectiveness analysis in health care. Handbooks in HealthEconomic evaluation","author":"A Gray","year":"2011","unstructured":"Gray A, Clarke P, Wolstenholme J, Wordsworth S. Applied methods of cost-effectiveness analysis in health care. Handbooks in HealthEconomic evaluation. Oxford: Oxford University Press; 2011."},{"issue":"5","key":"3162_CR44","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/j.1524-4733.2008.00502.x","volume":"12","author":"L Bojke","year":"2009","unstructured":"Bojke L, Claxton K, Sculpher M, Palmer S. Characterizing structural uncertainty in decision analytic models: a review and application of methods. Value Health. 2009;12(5):739\u201349. https:\/\/doi.org\/10.1111\/j.1524-4733.2008.00502.x .","journal-title":"Value Health"},{"issue":"49","key":"3162_CR45","first-page":"iii","volume":"8","author":"MJ Sculpher","year":"2004","unstructured":"Sculpher MJ, Pang FS, Manca A, Drummond MF, Golder S, Urdahl H, et al. Generalisability in economic evaluation studies in healthcare: a review and case studies. Health technology assessment (Winchester, England). 2004;8(49):iii\u2013v. 1-192","journal-title":"Health technology assessment (Winchester, England)"},{"issue":"5","key":"3162_CR46","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1177\/0272989X12458348","volume":"32","author":"AH Briggs","year":"2012","unstructured":"Briggs AH, Weinstein MC, Fenwick EAL, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working group\u20136. Med Decis Mak. 2012;32(5):722\u201332. https:\/\/doi.org\/10.1177\/0272989X12458348 .","journal-title":"Med Decis Mak"},{"key":"3162_CR47","volume-title":"Cost-effectiveness in health and medicine (2nd edition)","author":"M Sculpher","year":"2017","unstructured":"Sculpher M, Basu A, Kuntz K, Meltzer D. Reflecting uncertainty in cost-effectiveness analysis. In: Neumann PJSG, Russell LB, Siegel JE, Ganiats TG, editors. Cost-effectiveness in health and medicine (2nd edition). New York: Oxford University Press; 2017."},{"key":"3162_CR48","volume-title":"Advancing evidence generation for new drugs: IMI GetReal\u2019s Recommendationson real-world evidence","author":"GetReal I","year":"2017","unstructured":"GetReal I. Advancing evidence generation for new drugs: IMI GetReal\u2019s Recommendationson real-world evidence2017. http:\/\/www.imi-getreal.eu\/Publications\/Deliverables-and-reports."},{"key":"3162_CR49","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12916-017-0902-9","volume":"15","author":"R Kemp","year":"2017","unstructured":"Kemp R, Prasad V. Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused? BMC Med. 2017;15:134. https:\/\/doi.org\/10.1186\/s12916-017-0902-9 .","journal-title":"BMC Med"},{"issue":"3","key":"3162_CR50","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1017\/s0266462314000300","volume":"30","author":"O Ciani","year":"2014","unstructured":"Ciani O, Davis S, Tappenden P, Garside R, Stein K, Cantrell A, et al. Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers. Int J Technol Assess Health Care. 2014;30(3):312\u201324. https:\/\/doi.org\/10.1017\/s0266462314000300 .","journal-title":"Int J Technol Assess Health Care"},{"issue":"8","key":"3162_CR51","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1001\/jamainternmed.2015.2829","volume":"175","author":"V Prasad","year":"2015","unstructured":"Prasad V, Kim C, Burotto M, Vandross A. The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses. JAMA Intern Med. 2015;175(8):1389\u201398. https:\/\/doi.org\/10.1001\/jamainternmed.2015.2829 .","journal-title":"JAMA Intern Med"},{"issue":"3","key":"3162_CR52","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jval.2016.10.011","volume":"20","author":"O Ciani","year":"2017","unstructured":"Ciani O, Buyse M, Drummond M, Rasi G, Saad ED, Taylor RS. Time to review the role of surrogate end points in health policy: state of the art and the way forward. Value Health. 2017;20(3):487\u201395. https:\/\/doi.org\/10.1016\/j.jval.2016.10.011 .","journal-title":"Value Health"},{"key":"3162_CR53","volume-title":"Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA495)","author":"NICE","year":"2017","unstructured":"NICE. Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA495) 2017. https:\/\/www.nice.org.uk\/guidance\/ta495 ."},{"issue":"46","key":"3162_CR54","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3310\/hta16460","volume":"16","author":"K Claxton","year":"2012","unstructured":"Claxton K, Palmer S, Longworth L, Bojke L, Griffin S. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development. Health Technol Assess. 2012;16(46):323. https:\/\/doi.org\/10.3310\/hta16460 .","journal-title":"Health Technol Assess"}],"updated-by":[{"DOI":"10.1186\/s12913-019-4039-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T00:00:00Z","timestamp":1553731200000}}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-018-3162-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12913-018-3162-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-018-3162-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T05:48:12Z","timestamp":1720331292000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-018-3162-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,31]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3162"],"URL":"https:\/\/doi.org\/10.1186\/s12913-018-3162-2","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12913-019-4039-8","asserted-by":"object"}]},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,31]]},"assertion":[{"value":"9 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2019","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":".","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable \u2013 this article does not contain any studies with human participants or animals performed by any of the authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"AS has received consulting fees or honoraria from Roche, Gilead, Abbvie, Janssen and Novartis. MRM has received consulting fees from pharmaceutical companies with CDF-funded drugs, including Roche, Merck, Novartis, BMS and GSK, and has conducted clinical trials for which his institution is funded by the pharmaceutical industry. SR has received fees from Takeda for leadership training. RWB is a non-executive director of Celgene Corporation. LM and SW declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"393"}}